骨质疏松症的药物治疗

被引：82

作者：

冯颖 ^{[1
]}

修玲玲 ^{[1
]}

苏磊 ^{[2
]}

机构：

[1] 中山大学附属第一医院内分泌科

[2] 中山大学附属第一医院老年病科

来源：

医学综述 | 2014年 / 20卷 / 01期

关键词：

骨质疏松症; 治疗; 药物; 抗骨吸收剂; 促骨形成剂;

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

摘要：

骨质疏松症是一种骨退行性病变,其发生主要与骨吸收和骨重建失衡有关。根据骨质疏松症的发病机制的不同,临床治疗药物主要分为基本补充剂、抗骨吸收药物和促骨形成药物。钙剂和维生素D是药物治疗的基础;抗骨吸收药物包括双磷酸盐、雌激素及其受体调节剂、降钙素;甲状旁腺激素为促骨形成药物;锶盐、维生素K2等兼有抗骨吸收和促骨形成的作用。特殊人群以及不同类型的骨质疏松症治疗要注意药物的适用性和针对性。

引用

页码：105 / 109

页数：5

共 23 条

[1]

Osteoporosis: now and the future [J].

Rachner, Tilman D. ;

Khosla, Sundeep ;

Hofbauer, Lorenz C. .

LANCET, 2011, 377 (9773) :1276-1287

[2]

Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate.[J].BruceEttinger;San JavierMartin;GeraldCrans;ImrePavo.J Bone Miner Res.2009, 5

[3]

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial [J].

Reid, David M. ;

Devogelaer, Jean-Pierre ;

Saag, Kenneth ;

Roux, Christian ;

Lau, Chak-Sing ;

Reginster, Jean-Yves ;

Papanastasiou, Philemon ;

Ferreira, Alberto ;

Hartl, Florian ;

Fashola, Taiwo ;

Mesenbrink, Peter ;

Sambrook, Philip N. .

LANCET, 2009, 373 (9671) :1253-1263

[4]

Effects of treatment with fluoride on bone mineral density and fracture risk - a meta-analysis [J].

Vestergaard, P. ;

Jorgensen, N. R. ;

Schwarz, P. ;

Mosekilde, L. .

OSTEOPOROSIS INTERNATIONAL, 2008, 19 (03) :257-268

[5]

Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis [J].

Tang, Benjamin M. P. ;

Eslick, Guy D. ;

Nowson, Caryl ;

Smith, Caroline ;

Bensoussan, Alan .

LANCET, 2007, 370 (9588) :657-666

[6]

Treatment and prevention of osteoporosis.[J]..Wiener Medizinische Wochenschrift.2007, 23

[7]

Osteoporosis [J].

Sambrook, Philip ;

Cooper, Cyrus .

LANCET, 2006, 367 (9527) :2010-2018

[8]

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study [J].

Reginster, JY ;

Seeman, E ;

De Vernejoul, MC ;

Adami, S ;

Compston, J ;

Phenekos, C ;

Devogelaer, JP ;

Curiel, MD ;

Sawicki, A ;

Goemaere, S ;

Sorensen, OH ;

Felsenberg, D ;

Meunier, PJ .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (05) :2816-2822

[9]

Estimates of optimal vitamin D status [J].

Dawson-Hughes, B ;

Heaney, RP ;

Holick, MF ;

Lips, P ;

Meunier, PJ ;

Vieth, R .

OSTEOPOROSIS INTERNATIONAL, 2005, 16 (07) :713-716

[10]

Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (.[J].P. N. Sambrook;P. Geusens;C. Ribot;J. A. Solimano;J. Ferrer‐Barriendos;K. Gaines;N. Verbruggen;M. E. Melton.Journal of Internal Medicine.2004, 4

← 1 2 3 →